Clicky

Soleno Therapeutics, Inc.(SLNO) News

Date Title
Aug 15 Soleno Therapeutics stock falls after Scorpion Capital short report
Aug 11 How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15%
Aug 11 Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going
Aug 6 Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates
Aug 6 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results
Jul 28 Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET
Jul 25 Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Jul 23 Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect?
Jul 23 Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength
Jul 21 Soleno Therapeutics’ Vykat XR Exceeds Sales Expectations
Jul 16 Exploring US High Growth Tech Stocks with Promising Potential
Jun 26 TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
Jun 25 Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Jun 23 DoorDash, AMD upgraded: Wall Street's top analyst calls
Jun 20 Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Jun 20 Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
May 26 EMA validates Soleno’s application for Prader-Willi syndrome treatment
May 23 Soleno Therapeutics seeking regulatory approval in treatment of PWS
May 23 Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR
May 22 Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome